Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 112.00 | 0.94% | 11,994.00 | 11,994.00 | 12,000.00 | 12,018.00 | 11,854.00 | 11,860.00 | 2,284,602 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 26.44 | 184.24B |
From Mar 2020 to Mar 2025
LONDON--AstraZeneca PLC (AZN.LN) said on Tuesday the Phase III trial of an inhibitor, selumetinib, in combination with docetaxal chemotherapy to treat lung cancer, didn't meet its main endpoint and that the inhibitor didn't have "significant effect" on overall survival.
Selumetinib is being explored as a treatment option in studies in patients with differentiated thyroid cancer, the company said.
AstraZeneca bought worldwide rights to selumetinib from Array BioPharma Inc. in 2003, it said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
August 09, 2016 02:43 ET (06:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
